Medical Journals

Calmodulin Kinase Ii Inhibition Prevents Arrhythmic Activity Induced by Alpha and Beta Adrenergic Agonists in Rabbit Pulmonary Veins.

Authors:
  • Lo Li-Wei
  • Chen Yao-Chang
  • Chen Yi-Jen
  • Wongcharoen Wanwarang
  • Lin Cheng-I
  • Chen Shih-Ann

From: National Yang-Ming University, School of Medicine, Division of Cardiology and Cardiovascular Research Center, Taipei Veterans General Hospital, Taiwan.

European journal of pharmacology

  • Publish Date: Oct 2007
  • ISSN: 0014-2999
  • Volume: 571
  • Issue: 2-3
  • Pages: 197-208
  • Medium: Print
  • Language: English
  • Citation (JAMA): Lo Li-Wei, Chen Yao-Chang, Chen Yi-Jen, et al. Calmodulin Kinase Ii Inhibition Prevents Arrhythmic Activity Induced by Alpha and Beta Adrenergic Agonists in Rabbit Pulmonary Veins.. Eur. J. Pharmacol. Oct 2007;571:197-208

Abstract

The autonomic nervous system and calcium regulation play important roles in the pathophysiology of atrial fibrillation. Calmodulin regulates the calcium homeostasis and may mediate the proarrhythmic effects of autonomic nervous agents. The purpose of this study was to compare the effects of beta- and alpha-adrenoceptor agonists on the pulmonary vein electrical activity and evaluate whether calmodulin kinase II inhibitors may change the effects of the adrenoceptor agonists on the pulmonary vein arrhythmogenesis. Conventional microelectrodes were used to record the action potentials in isolated rabbit pulmonary vein tissue specimens before and after the administration of isoproterenol, phenylephrine and KN-93 (a calmodulin kinase II inhibitor). In the tissue preparation, isoproterenol (0, 0.1, 3 microM) increased the beating rates (1.5+/-0.2, 1.6+/-0.2, 2.3+/-0.3 Hz, n=10, P<0.001) with the genesis of early afterdepolarizations (EADs, 0%, 40%, 50%, P<0.05) and increased the amplitude of the delayed afterdepolarizations (DADs, 0.6+/-0.3, 1.7+/-0.4, 3.9+/-1.0 mV, P<0.05). Phenylephrine (0, 1, 10 microM) also increased the beating rates (1.4+/-0.2, 1.6+/-0.2, 1.9+/-0.2 Hz, n=12, P<0.001), incidence of EADs (0%, 8%, 50%, P<0.05) and amplitude of the DADs (0.4+/-0.2, 1.2+/-0.4, 2.6+/-0.8 mV, P<0.05). KN-93 did not change the pulmonary vein beating rates or action potential duration. However, in the presence of KN-93 (1 microM), isoproterenol (3 microM) and phenylephrine (10 microM) did not induce any EADs or DADs in the pulmonary veins. In conclusion, calmodulin kinase II inhibition may prevent adrenergic induced pulmonary vein arrhythmogenesis.

Mesh Headings (Keywords): Action Potentials, Adrenergic alpha-Agonists, Adrenergic beta-Agonists, Animals, Anti-Arrhythmia Agents, Atrial Fibrillation, Benzylamines, Calcium-Calmodulin-Dependent Protein Kinase Type 2, Calcium-Calmodulin-Dependent Protein Kinases, Dose-Response Relationship, Drug, Isoproterenol, Kinetics, Phenylephrine, Protein Kinase Inhibitors, Pulmonary Veins, Rabbits, Sulfonamides


Check for Full Text / PubMed Unique Identifier (PMID): 17612522


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.